COVID-19 Nucleic Acid Amplification Tests (NAATs) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update

PUBLISHED: December 19, 2023

PAGES: 22 Pages

DELIVERY TIME: 1-2 business days

SELECT AN OPTION

GlobalData's Medical Devices sector report, "COVID 19 Nucleic Acid Amplification Tests (NAATs) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update" provides comprehensive information about the COVID 19 Nucleic Acid Amplification Tests (NAATs) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

NAAT involves amplification of specific nucleic acid sequences of SARS-CoV-2 virus by targeting specific nucleic acid sequences. NAAT exhibits better sensitivity in comparison to antigen identification methods. Multiple targets are used in PCR to detect the different types of SARS-Cov-2.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

Extensive coverage of the COVID 19 Nucleic Acid Amplification Tests (NAATs) under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of COVID 19 Nucleic Acid Amplification Tests (NAATs) and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment / industry

Reasons to Buy

The report enables you to -

Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
Identify and understand important and diverse types of COVID 19 Nucleic Acid Amplification Tests (NAATs) under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product's current stage of development, territory and estimated launch date

1 Table of Contents

1.1 List of Tables
1.2 List of Figures

2 Introduction

2.1 COVID 19 Nucleic Acid Amplification Tests (NAATs) Overview

3 Products under Development

3.1 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Stage of Development
3.2 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Territory
3.3 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Regulatory Path
3.4 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Ongoing Clinical Trials

4 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products under Development by Companies

4.1 COVID 19 Nucleic Acid Amplification Tests (NAATs) Companies - Pipeline Products by Stage of Development
4.2 COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Stage of Development

5 COVID 19 Nucleic Acid Amplification Tests (NAATs) Companies and Product Overview

5.1 Age Labs AS Company Overview
- 5.1.1 Age Labs AS Pipeline Products & Ongoing Clinical Trials Overview
5.2 Chengdu One-Chip Biotechnology Co Ltd Company Overview
- 5.2.1 Chengdu One-Chip Biotechnology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview

6 COVID 19 Nucleic Acid Amplification Tests (NAATs)- Recent Developments

6.1 Nov 29, 2023: BioSkryb Genomics Appoints Genomics Industry Veteran Ram Laxman as Chief Commercial Officer
6.2 Oct 30, 2023: Cepheid Receives 510(K) Clearance For Xpert Xpress CoV-2 Plus Test
6.3 Mar 17, 2023: When time matters, rapid point of care testing can support treatment decisions
6.4 Mar 15, 2023: Cepheid receives Health Canada Licence for Xpert Xpress CoV-2 plus

7 Appendix

7.1 Methodology
7.2 About GlobalData
7.3 Contact Us
7.4 Disclaimer

List of Tables

COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Stage of Development
COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Territory
COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Regulatory Path
COVID 19 Nucleic Acid Amplification Tests (NAATs) - Ongoing Clinical Trials
COVID 19 Nucleic Acid Amplification Tests (NAATs) Companies - Pipeline Products by Stage of Development
COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Stage of Development
Glossary

List of Figures

COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Stage of Development
COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Territory
COVID 19 Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Regulatory Path
COVID 19 Nucleic Acid Amplification Tests (NAATs) - Ongoing Clinical Trials